Sensitivity analysis results show that changing the effect models had no significant effects on the pooled OR, HR and the final strength of the association between GSTP1 IIe105Val, GSTM1 and GSTT1 null or present genetic polymorphisms and the clinical outcome of platinum-based chemotherapy to NSCLC patients. This evidence concerns the gene GSTM1 and non-small cell lung carcinoma.